Enveda Biosciences Named One of Biotech’s Most Promising Startups by Endpoints News

BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a biotechnology company discovering new medicines from the natural world, has been chosen by the Endpoints News editorial team as one of the most promising biotech startups in this year’s Endpoints 11 annual special report.

Enveda has built a first of its kind platform for industrial scale natural product drug discovery. While natural products are a proven source of impactful medicines, identifying and characterizing drug-like bioactive, therapeutic compounds from the thousands of other molecules present in a plant has historically proven challenging. Using a combination of advanced machine learning methodologies and a next generation metabolomics-based platform, Enveda has addressed these rate limiting steps, creating a vast, highly diverse, and easily searchable proprietary library of high-potential drug leads.

“On behalf of the entire team at Enveda, we are honored that John Carroll and the editors of Endpoints recognize the value of our efforts to learn from life, taking the molecules created by evolution and turning them into medicines that make a difference to patients,” says Viswa Colluru, Ph.D., founder and CEO of Enveda Biosciences.

Enveda’s platform and library has already yielded four development candidates, with three additional candidates in fast follow. The two lead compounds both target inflammation. The first addresses inflammatory bowel disease through a novel MOA and biodistribution. The second, addressing atopic dermatitis, inhibits neutrophil migration through a unique MOA, blocking multiple chemoattractant pathways with a single molecule. Both of these compounds are slated to enter clinical trials in 2024.

“While our initial focus is on diseases associated with inflammation, we believe that nature contains the solutions to an immense range of problems, both in and out of the clinic. Our platform is super-powering our ability to find and utilize these solutions, and we’re grateful to the Endpoints team for highlighting the importance of this work,” says Colluru.

About Enveda Biosciences

Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine from the expanse of nature’s unknown chemistry, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of experience in the pharmaceutical industry working with preeminent data scientists. For more information on Enveda, visit envedabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230921086623/en/